José Antonio Gil-Montoya1,2, Rocío Barrios3, Inés Sánchez-Lara3, Cristobal Carnero-Pardo4, Francisco Fornieles-Rubio5, Juan Montes6, Miguel Angel Gonzalez-Moles3, Manuel Bravo3. 1. Bio-Health Research Institute of Granada, School of Dentistry, Granada, Spain. jagil@ugr.es. 2. Facultad de Odontología, Universidad de Granada, c/ Paseo de Cartuja s/n, 18071, Granada, Spain. jagil@ugr.es. 3. Bio-Health Research Institute of Granada, School of Dentistry, Granada, Spain. 4. Neurology Department, Virgen de las Nieves University Hospital, Granada, Spain. 5. Unit of Clinical Management Oro-Dental Health Granada-Metropolitan, Granada, Spain. 6. Neurology Department, "San Cecilio" University Hospital, Granada, Spain.
Abstract
BACKGROUND: Older adults, especially those with cognitive impairment or dementia, frequently consume drugs with potential xerostomic effects that impair their quality of life and oral health. OBJECTIVES: The objective of this study was to determine the prevalence and analyze the possible pharmacological etiology of xerostomia in older people with or without cognitive impairment. METHODS: Individuals with cognitive impairment were recruited from patients diagnosed using standardized criteria in two neurology departments in Southern Spain. A comparison group was recruited from healthcare centers in the same city after ruling out cognitive impairment. Data on oral health, xerostomia, and drug consumption were recorded in both groups. Dry mouth was evaluated using a 1-item questionnaire and recording clinical signs of oral dryness. All drugs consumed by the participants were recorded, including memantine, anticholinesterases, antipsychotics, antidepressants, and anxiolytics. RESULTS: The final sample comprised 200 individuals with mild cognitive impairment or dementia and 156 without. Xerostomia was present in 70.5 % of participants with cognitive impairment versus 36.5 % of those without, regardless of the drug consumed. Memantine consumption was the only variable significantly related to xerostomia in the multivariate model (OR 3.1; 95 % CI 1.1-8.7), and this relationship persisted after adjusting for possible confounders and forcing the inclusion of drugs with xerostomic potential. CONCLUSIONS: More than 70 % of participants diagnosed with cognitive impairment or dementia had xerostomia. Anticholinesterases and memantine were both associated with the presence of xerostomia. In the case of memantine, this association was independent of the consumption of the other drugs considered.
BACKGROUND: Older adults, especially those with cognitive impairment or dementia, frequently consume drugs with potential xerostomic effects that impair their quality of life and oral health. OBJECTIVES: The objective of this study was to determine the prevalence and analyze the possible pharmacological etiology of xerostomia in older people with or without cognitive impairment. METHODS: Individuals with cognitive impairment were recruited from patients diagnosed using standardized criteria in two neurology departments in Southern Spain. A comparison group was recruited from healthcare centers in the same city after ruling out cognitive impairment. Data on oral health, xerostomia, and drug consumption were recorded in both groups. Dry mouth was evaluated using a 1-item questionnaire and recording clinical signs of oral dryness. All drugs consumed by the participants were recorded, including memantine, anticholinesterases, antipsychotics, antidepressants, and anxiolytics. RESULTS: The final sample comprised 200 individuals with mild cognitive impairment or dementia and 156 without. Xerostomia was present in 70.5 % of participants with cognitive impairment versus 36.5 % of those without, regardless of the drug consumed. Memantine consumption was the only variable significantly related to xerostomia in the multivariate model (OR 3.1; 95 % CI 1.1-8.7), and this relationship persisted after adjusting for possible confounders and forcing the inclusion of drugs with xerostomic potential. CONCLUSIONS: More than 70 % of participants diagnosed with cognitive impairment or dementia had xerostomia. Anticholinesterases and memantine were both associated with the presence of xerostomia. In the case of memantine, this association was independent of the consumption of the other drugs considered.
Authors: Bing Liu; Michael R Dion; M Marianne Jurasic; Gretchen Gibson; Judith A Jones Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Date: 2012-05-04
Authors: José A Gil-Montoya; Ines Sanchez-Lara; Cristobal Carnero-Pardo; Francisco Fornieles; Juan Montes; Rosa Vilchez; J S Burgos; M A Gonzalez-Moles; Rocío Barrios; Manuel Bravo Journal: J Periodontol Date: 2014-10-27 Impact factor: 6.993
Authors: E Bufill; A Bartés; A Moral; T Casadevall; M Codinachs; E Zapater; J C Rovira; R Pérez; P Roura; R Blesa Journal: Neurologia Date: 2009-03 Impact factor: 3.109
Authors: Suzanne Delwel; Tarik T Binnekade; Roberto S G M Perez; Cees M P M Hertogh; Erik J A Scherder; Frank Lobbezoo Journal: Clin Oral Investig Date: 2017-11-15 Impact factor: 3.573
Authors: Mara-Zoe Hummelsheim; Stefanie Hamacher; Anna Hagemeier; Michael Johannes Noack; Anna Greta Barbe Journal: Sci Rep Date: 2021-10-14 Impact factor: 4.379
Authors: Dorina Lauritano; Giulia Moreo; Fedora Della Vella; Dario Di Stasio; Francesco Carinci; Alberta Lucchese; Massimo Petruzzi Journal: Int J Environ Res Public Health Date: 2019-11-18 Impact factor: 3.390